Virpax shares rise on expanded licensing deal for experimental drug
READ OTHER MEDIA
HOME
ABOUT
PRODUCTS
PORTFOLIO
BEHIND THE SCIENCE
PUBLICATIONS
TEAM
INVESTORS
RECENT MEDIA
CONTACT
Presentations
Press Releases
Events
Presentations
Leadership
Governance
SEC Fillings
Stock Quote
Analyst Coverage
Email Alerts
Investor FAQs
October 19, 2022
Investor Presentation
October 19, 2022
Corporate Overview
BUSINESS INQUIRIES
Virpax Pharmaceuticals, Inc.
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312
610.727.4597
info@virpaxpharma.com
INVESTOR INQUIRIES
Betsy Brod
Affinity Growth Advisors
betsy.brod@affinitygrowth.com
MEDIA INQUIRIES
Public Relations
Virpax Pharmaceuticals, Inc.
pr@virpaxpharma.com